Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.37 USD
0.00 (0.00%)
Updated Apr 26, 2024 03:59 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KZIA 0.37 0.00(0.00%)
Will KZIA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KZIA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KZIA
Beat the Market the Zacks Way: Kazia Therapeutics, Uber, Medtronic in Focus
Novogen Limited (KZIA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
KZIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novogen Limited (KZIA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Here's Why Novogen Limited (KZIA) Is a Great 'Buy the Bottom' Stock Now
Other News for KZIA
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics licenses paxalisib to Sovargen